论文部分内容阅读
目的:分析del(17p13)(TP53)与多发性骨髓瘤患者临床资料的关系及其对预后的影响。方法:收集56例初诊多发性骨髓瘤患者临床资料,并对其骨髓标本行荧光原位杂交(fluorescence in situ hybridization,FISH)检测。统计软件采用SPSS 19.0,研究del(17p13)与临床基本资料间的关系使用卡方检验,与实验室检查指标间的关系使用t检验。生存分析使用Kaplan-Meier法。结果:初诊多发性骨髓瘤(multiple myeloma,MM)患者del(17p13)缺失的检出率为21.43%。Del(17p13)与乳酸脱氢酶(lactate dehydrogenase,LDH)水平相关联(P=0.034),与性别、年龄、分型、D-S分期、ISS分期、血小板、白蛋白、球蛋白、β2微球蛋白、尿素氮、血肌酐、血钙、骨髓瘤细胞比例无关。Del(17p13)患者的无进展生存期(progression free survival,PFS)及总生存期(overall survival,OS)均较未缺失者显著缩短(P<0.05)。结论:本研究发现del(17p13)与部分临床特征相关,del(17p13)的MM患者预后不良。
Objective: To analyze the relationship between del (17p13) (TP53) and clinical data in patients with multiple myeloma and its impact on prognosis. Methods: The clinical data of 56 patients with newly diagnosed multiple myeloma were collected and their bone marrow samples were detected by fluorescence in situ hybridization (FISH). Statistical software using SPSS 19.0, research del (17p13) and clinical data using the relationship between the chi-square test, and the relationship between laboratory tests using t test. Survival analysis using Kaplan-Meier method. Results: The detection rate of del (17p13) deletion in newly diagnosed multiple myeloma (MM) patients was 21.43%. Del (17p13) was associated with lactate dehydrogenase (LDH) level (P = 0.034), but not with sex, age, type, DS stage, ISS stage, platelet, albumin, globulin, β2 microglobulin , Urea nitrogen, serum creatinine, serum calcium, myeloma cells had no relationship. The progression free survival (PFS) and overall survival (OS) of Del (17p13) patients were significantly shorter than those without deletion (P <0.05). Conclusion: This study found that del (17p13) was associated with some clinical features and that del (17p13) MM patients had poor prognosis.